References
- Janku J. Pathogenesa a pathologika anatomie tak nazvaneho vrozenehonalezem parasitu v stinici. Car. Lek. Ces. 62, 1021–1027 (1923).
- Koch FLP, Wolf A, Cowen D, Paige BH. Toxoplasmic encephalomyelitis: VII. Significance of ocular lesions in the diagnosis of infantile, or congenital toxoplasmosis. Arch. Ophthalmol 29,1 (1943).
- Couvreur G. Etude de la toxoplasmose congénitale a propose de 20 observations. These. Paris, France, (1956).
- Sabin AB, Warren J. Therapeutic effectiveness of certain sulfonamides on infection by an intracellular protozoan (Toxoplasma). Proc. Soc. &pr. Biol. Med. 51,19–23 (1942).
- Eyles DE. The present status of the chemotherapy of Toxoplasmosis. Am. J. 7i-op. Med. Hyg. 2,429-444 (1953).
- Eyles DE, Coleman N. Tests of 2,4-diaminopyrimidines on toxoplasmosis. Pub. I-ith Rep. 67,249–52 (1952).
- Beverly JKA. A rational approach to the treatment of toxoplasma uveitis. Trans. Ophthalmol Soc. UK78, 109–121 (1958)
- Garin P, Eyles DE. Le traitement de la toxoplasmose expérimentale de la souris par la Spiramycine. Nouv. Press Mod. 66, 254–260 (1958).
- Feldman HA. Congenital toxoplasmosis — a study of 103 cases. Am J. Dis. Child 86, 487–95 (1953)
- Koppe JG, Loewer-Sieger DH, Roever-Bonnet H de. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 254–256 (1986).
- •The only study reporting long term follow up of untreated patients.
- Petersen E, Dubey JP. Biology of Toxoplasmosis, In: Clinical Toxoplasmosis: Prevention and Management. Joynson DHM, Wreghitt TG (Eds). Cambridge University Press, UK, 1–42 (2001).
- Scholer HJ, Leimer R, Richle R. Sulfonamides and sulphones. In: Antimalarial Drugs II Peters W, Richards WHG (Eds). Springer-Verlag, Berlin, Germany, 123–206 (1984).
- Garin JP, Sung RTM, Mojon M, Paillard B. Guérison de la toxoplasmose expérimentale de la souris par l'association sulfadoxine-pyriméthamine. propositions d'application a l'homme. Lyon Med. 236,19–23 (1976).
- Phillips-Howard PA, West U. Serious adverse drugs reactions to pyrimethamine-sulfadoxine, pyrimethamine-dapsone and amodiaquine in Britain. J. R. Soc. Med. 83, 82–85 (1990).
- Kavi J, Webberley JM, Andrews JM, Wise R. A comparison of the pharmacokinetics and tissue penetration of spiramycin and erythromycin. J. Antimicrob. Chemother. 22 (Suppl. B), 105–110 (1988).
- Schoondermark VVE, Galama J, Camps W, Vree T, Russel F, Meuwissen J. Pharmacokinetics of spiramycin in the Rhesus monkey: Transplacental passage and distribution in the tissue in the fetus. Antimicrob. Agents Chemother 38, 1930–1936 (1994).
- •A tightly controlled study in a primate model which can be extrapolated to humans.
- Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J. Infect. Dis. 164,170–177 (1991).
- Derouin F, Almadany R, Chau F, Rouveix B, Pocidalo JJ. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. Antimicrob. Agents Chemother. 36,997–1001 (1992).
- Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MSA, Ruyven RU, Klok AM, Hoyng CB, Rothova A. A prospective, randomised trial of pyrimethamine and azithromycin versus pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am j Ophthalmol 134, 34–40 (2002).
- World Health Organisation. Report of the WHO consultation on Public Health Aspects of Toxoplasmosis. WHO/CDS/VPH/88 [74]. (1988).
- Remington JS, McLeod R, Thulliez P, Desmonts G. Toxoplasmosis. In: Infectious Diseases of the Fetus and Newborn Infant (5th Edition). Remington JS, Klein JO (Eds). WB Saunders, PA, USA, 205–346 (2000).
- Silveira C, Belfort R, Muccioli C, etal The effect of long-term, intermittent trimethoprimisulfamethoxazole treatment of recurrences of toxoplasmic retinochoiditis. Am. j Ophthalmol 134, 41–46 (2002).
- •Randomized trial demonstrating the effects of long-term prophylaxis with trimethoprim/sulfamethoxazole in preventing new lesions.
- Couvreur J, Desmonts G. Congenital and maternal toxoplasmosis. A review of 300 congenital cases. Develop. Med. Child Neural 4,519–530 (1962).
- Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 66,767–774 (1980).
- McAuley J, Boyer KM, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: The Chicago Collaborative Treatment Trial. Clin. Infect. Dis 18, 38–72 (1994)
- •The largest study of severely affected children referred to a reference center.
- Guerina NG, Ho-Wen H, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl. I Med. 330,1858–1863 (1994).
- •The largest descriptive study of children identified by neonatal screening and followed for up to 8 years.
- Fuchs HJ, Fledelius HC, Schmidt DR, Petersen E. A 6-year ophthalmic follow-up of children born 1992–1996 with congenital toxoplasmosis in Denmark. International Conference on Toxoplasmosis. Copenhagen 23–25 June (2003) (Abstract).
- •Descriptive study of children identified by neonatal screening and followed for 6 years after 3 month treatment with sulfadiazine and pyrimethamine.
- Villena I, Aubert D, Leroux B, etal. Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: Follow-up of 78 cases between 1980 and 1997. Scand. Infect. Dis. 30,295–300 (1998).
- •Longitudinal study with historical controls describing the effect of up to 24 months continuous prophylaxis with sulfadoxine and pyrimethamine.
- Gilbert R, Dunn D, Wallon M, etal. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment period. Epidemial Infect. 127,113–20 (2001).
- •Descriptive study of different cohorts identified by different algorithms of pre-and neonatal screening.
- Foulon W, Villena I, Stray-Pedersen B, et al Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am j Obstet. Cynecol 180,410–415 (1999).
- •Retrospective study partially taking gestational age at infection into account, which may include referred cases with symptoms.
- Gras L, Gilbert RE, Ades AE, Dunn DT Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int. Epidemial 30,1309–1313 (2001).
- •A retrospective analysis of 181 children born to infected mothers.
- Gilbert R, Gras L, the European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BE. 1. Obsts. Cynaecol 110,112-120 (2003).
- •The largest ever performed prospective cohort study comparing the outcome at one year of age in children identified by the French and Austrian pre-natal screening algorithm and neonatal screening as practised in Denmark.
- Couvreur J, Nottin N, Desmonts G. La Toxoplasmose congenitale traitee. Ann. Pediab: (Paris) 27,647–652 (1980).
- Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 66,767–774 (1980).
- Couvreur J, Desmonts G, Aron-Rosa D. Le prognostic oculaire de la toxoplasmose congenitale: rale du traitements. Ann. Pediab: (Paris) 31,855–858 (1984).
- Maisonneuve H, Faber C, Piens MA, Garin JR Tolerance de l'association sulfadoxine-pyrimethamine. Vingt-quatre observations. Presse Med. 13,859–862 (1984).
- Koppe JG, Loewer-Sieger, DH, Roever-Bonnet H de. Results of a 20-year follow-up of congenital toxoplasmosis. Lancet 254–256 (1986).
- Hohlfeld P, Daffos F, Thulliez P, Aufrant C, Couvreur J, MacAleese J, et al. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up af-ter in utero treatment. Pediab: 115,765–769 (1989).
Website
- www.silverplattencom